Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
Cobra Biologics is pleased to announce the appointment of Daniel Smith as Chief Scientific Officer with the responsibility of enhancing Cobra’s DNA, virus, microbial and mammalian proteins research and development platforms. 7 May 2014
UK-based cancer therapeutics firm Scancell has announced the appointment of Sally Adams to the board as Development Director with immediate effect. 1 May 2014
UK nanotechnology firm Midatech has announced the appointments of Rolf Stahel as chairman and Craig Cook as Chief Operating Officer (COO) and Chief Medical Officer (CMO). 1 May 2014
US biopharmaceutical company Coherus Biosciences has announced the appointment of Michael Fleming as senior vice president, commercial strategy. 28 April 2014
UK-based antiviral drug discovery and development company reViral has announced the appointment of Professor Raymond Schinazi to its Board as a Non-Executive Director, effective from 9 April 2014. 28 April 2014
Novartis Vaccines, the vaccination branch of Swiss drug major Novartis (NOVN: VX), has announced the appointment of Dr John Porter to the position of Medical Affairs Director for Cluster North Europe. 25 April 2014
Digital medicines company Proteus Health, have announced the expansion of the company’s executive team and board of directors with the addition of three industry leaders across consumer technology and global pharmaceuticals. 25 April 2014
China’s WuXi PharmaTech (NYSE: WX) has announced that Dr Steve Yang has joined the company as Executive Vice President and Chief Operating Officer. Edward Hu will assume new responsibilities as Chief Investment Officer and remain as Chief Financial Officer. 24 April 2014
US generic drugmaker Impax Laboratories (NASDAQ: IPXL) has announced the appointment of Frederick Wilkinson as President and Chief Executive Officer effective April 29, 2014. 24 April 2014
Adaptimmune, a biotech company focused on the use of engineered T cells to treat cancer, has announced the full-time appointment of James Noble as chief executive officer. 26 March 2014
German pharma and chemical major Merck KGaA has announced the promotion of three distinguished internal managers to head the life-science-tools and consumer health divisions as well as its allergy business unit. 26 March 2014
Australian product development company Clinical Network Services (CNS) has launched a new UK office headed by Paul Cronin who joins as UK Director and Director, Business Development. 10 March 2014
French biopharmaceutical company Genticel has recruited Sophie Olivier as chief medical officer to lead the clinical development of its pipeline, in particular the ProCervix Phase II trial. 4 March 2014